Vesicar (solifenacin) in the treatment of urinary bladder hyperactivity


如何引用文章

全文:

详细

Urinary bladder hyperactivity (UBH) is highly prevalent chronic disease. The pharmaceutical market has enough variants of antimuscarinic drugs, nonselective (oxybutynin, tolterodine, trospium chloride, propiverin) and selective (solifenacin, darifenacin), which are used in the treatment of UBH. The article includes the results of many randomized multicentral trials in which efficiency and safety of solifenacin (Vesicar) was evaluated. It was shown that treatment by solifenacin decreases the symptoms of UBH and improves patients quality of life. The main advantages of solifenacin are possibility to change the dosage depending on symptoms severity and simplicity of treatment (once a day). Because of the small number of adverse effects solifenacin (Vesicar) it can be recommended as a gold standard of UBH treatment in all patients groups.

参考

  1. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-66.
  2. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36.
  3. Abrams P, Wein AJ. The overactive bladder: from basic science to clinical management. Urology 1997;50(Suppl. 6A):1-144.
  4. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 2002;21:167-78.
  5. Cardozo L, Robinson D. Special considerations in premenopausal and postmenopausal women with symptoms of overactive bladder. Urology 2002;60(Suppl. 5A):64−71.
  6. Ouslander JG. Geriatric considerations in the diagnosis and management of overactive bladder. Urology 2002;60(Suppl. 5A):50−55.
  7. Yap P, Tan D. Urinary incontinence in dementia. A practical approach. Aus Fam Physician 2006;35:237−41.
  8. Djavan B. Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient's quality of life. Urology 2003;62(3 Suppl. 1):6−14.
  9. Abrams P, Artbani W, Gajewski JB, Hussain I. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 2006;68(Suppl. 2A):17−28.
  10. International Continence Society. Management recommendations. In: Abrams P, Cardozo L, Khoury S, Wein A (eds). 3rd International Consultation on Incontinence, 2005.
  11. Hampel C, Hohenfellner M, Abrams P, et al. European Association of Urology. Guidelines on incontinence. 1999.
  12. Wein AJ. Diagnosis and treatment of the overactive bladder. Urology 2003;62(Suppl. 5B):20−27.
  13. Norton P, Brubaker L. Urinary incontinence in women. Lancet 2006;367:57−67.
  14. Ostaszkiewicz J, Johnston L, Roe B. Timed voiding for the management of urinary incontinence in adults. Cochrane Database Syst Rev 2004.
  15. Burgio KL. Influence of behavior modification on overactive bladder. Urology 2002;60(Suppl. 5A):72−77.
  16. Wallace SA, Roe B, Williams K, et al. Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev 2003; CD001308.
  17. Salvatore S, Soligo M, Proietti F, et al. Overactive bladder syndrome: considerations in pharmacotherapy and new perspectives. Eur J Obstet Gynecol Reprod Biol 2005;120:129−33.
  18. Marieb EN. The urinary system. In: Human anatomy & physiology. 5th ed. San Francisco: Benjamin Cummings, 2001.
  19. Dmochowski RR, Appell RA. Advancements in pharmacologic management of the overactive bladder. Urology 2000;56(Suppl. 6A):41−49.
  20. Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacology 2006;147:S80−S87.
  21. Vesicare. Summary of product characteristics, September 2005.
  22. Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004;492:243−50.
  23. Chapple CR, Arano P, Bosch JLHR, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004;93:71−77.
  24. Brunton S, Kuritzky L. Recent developments in the management of overactive bladder. Curr Med Res Opin 2005;21:71−80.
  25. Chu F, Smith N. Efficacy and safety of 10 mg solifenacin succinate, a once-daily antimuscarinic agent, in a randomised, double-blind, placebo-controlled trial in patients with overactive bladder. IN PROGRESS.
  26. Govier FE, Smith N. A randomised, double-blind, placebo-controlled study to assess the efficacy and safety of 10 mg solifenacin succinate trial in patients with overactive bladder syndrome. IN PROGRESS.
  27. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303−10.
  28. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172:1919-24.
  29. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended-release tolterodine at treating overactive bladder syndrome: Results of the STAR Trial. Eur Urol 2005;48:464−70.
  30. Toglia M, Andoh M, Hussain I. Solifenacin improves urgency symptoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder. International Continence Society annual meeting, 2006. Abstract 155.
  31. Chancellor M, Whitmore K, Snyder J, et al. Solifenacin treatment of overactive bladder in patients previously treated with tolterodine extended release. Obstet Gynecol. Details TBC.
  32. Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the Vesicare Open-Label Trial (VOLT). Clin Ther 2006;28:1935-46.
  33. Samuels TA, Mitcheson HD, Vardy MD, et al. Solifenacin significantly improves overactive bladder symptoms, symptom-associated bother and other patient-related outcomes:Results from VIBRANT, a double-blind, placebo-controlled trial. EAU annual meeting, 2009. Abstract 190.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##